Does Singulair (montelukast) need to be taken at night?

Timing of Singulair (Montelukast) Administration

For asthma, Singulair should be taken once daily in the evening, as explicitly stated in the FDA-approved prescribing information 1. However, for allergic rhinitis alone, the timing can be individualized and does not need to be restricted to evening dosing 1.

Indication-Specific Dosing Recommendations

Asthma

• Evening administration is the FDA-recommended timing 1
• The label explicitly states: "For asthma, administer SINGULAIR orally once daily in the evening, with or without food"
• Important caveat: The FDA label acknowledges that "there have been no clinical trials in patients with asthma to evaluate the relative efficacy of morning versus evening dosing" 1

Allergic Rhinitis

• Timing is flexible - can be taken at any time of day 1
• The FDA label states: "Time of administration in patients with allergic rhinitis can be individualized to suit patient needs"
• This applies to both seasonal and perennial allergic rhinitis

Combined Asthma and Allergic Rhinitis

• Take once daily in the evening 1
• Only one dose should be taken per day for patients with both conditions

Evidence Supporting Flexible Timing

Research evidence suggests the evening recommendation for asthma may be more traditional than evidence-based:

• A pediatric study directly comparing morning versus evening dosing for exercise-induced bronchoconstriction found no statistical difference in effectiveness between morning and evening administration 2
• Both timing regimens provided significant protection against exercise-induced bronchoconstriction compared to pretreatment values
• The original clinical trials establishing montelukast's efficacy used evening dosing 3, 4, which likely established the convention rather than proving superiority

Critical Safety Considerations

Before prescribing montelukast at any time of day, you must consider the FDA Black Box Warning 1:

• Serious neuropsychiatric events including agitation, aggression, depression, sleep disturbances, and suicidal thoughts/behavior have been reported
• For allergic rhinitis, reserve montelukast only for patients with inadequate response or intolerance to alternative therapies (such as intranasal corticosteroids) 1
• The 2020 asthma guidelines note that montelukast is now considered an alternative rather than preferred therapy, with limited availability considerations 5

Patient Counseling Requirements

• Discuss benefits and risks before prescribing
• Advise patients/caregivers to monitor for behavioral changes or new neuropsychiatric symptoms
• Discontinue immediately if such symptoms occur 1

Practical Algorithm

1. Determine indication:

   • Asthma or asthma + allergic rhinitis → Evening dosing
   • Allergic rhinitis alone → Any time of day
   • Exercise-induced bronchoconstriction → At least 2 hours before exercise (not daily dosing)

2. Ensure appropriate patient selection given safety concerns

3. Counsel on neuropsychiatric risks before initiating therapy

4. Monitor treatment response within 4-6 weeks and discontinue if no clear benefit 5